Abstract: Engineered Cas12a guide RNA (gRNA) molecules useful, for example, for correcting aberrant RNA splicing resulting from mutations in a genomic DNA sequence and for preventing exon inclusion in mature mRNA.

Abstract: This invention relates generally to a process to perform controlled alkaline and acid treatments on inorganic porous solids, yielding superior physico-chemical and catalytic properties, whereas the particle and crystal size is not negatively influenced. Accordingly, the solids obtained in this fashion can be easily recovered from the alkaline solution. The latter being problematic in the state of the art.

Abstract: Disclosed herein are cell differentiating systems for differentiating cells. The systems comprise an input means for receiving a reconstructed image of a cell based on a holographic image of the cell in suspension, and a cell recognition means for determining cell characterization features from the reconstructed image of the cell for characterization of the cell. The cell recognition means thereby is configured for determining, as cell recognition features, image moments.

Abstract: Embodiments relate to a sensor structure for an acoustical pressure sensor and an opto-mechanical sensor and system that may be used for detecting acoustical pressure waves. Embodiments of a sensor structure for an acoustical pressure sensor include an optical waveguide closed-loop resonator and a plurality of sensor elements. The individual sensor elements of the plurality of sensor elements are configured to be affected by an acoustical pressure wave such that a physical property of the individual sensor element is changed. The optical waveguide closed-loop resonator is arranged at the plurality of sensor elements and associated with each of the individual sensor elements such that a resonance frequency of the optical waveguide closed-loop resonator is shifted due to the affected physical properties of all individual sensor elements. The sensor structure provides a high sensitivity from each sensor element, which is advantageous in e.g.

Abstract: A reconfigurable logic circuit comprises first, second and third switching circuits arranged for receiving first, second and third input bits, respectively, and each arranged for being configured in a mode wherein the corresponding input bit is passed on or in a mode; a first exclusive OR logic block operable on the outputs of the first, second and third switching circuits and arranged to output a sum bit; fourth, fifth and sixth switching circuits arranged for receiving a fourth, fifth and sixth input bits and arranged for being configured in a mode; first, second and third AND logic blocks, each arranged for receiving a different pair of the outputs of certain switching circuits; a second exclusive OR logic block operable on the outputs of certain AND logic blocks and arranged to produce a carry output bit.

Abstract: The invention provides a compartmentalised gel matrix comprising one or more compartments, wherein each compartment comprises a volume of hydrophobic medium and one or more aqueous droplets therein. The invention further provides a pharmaceutical formulation comprising a compartmentalised gel matrix according to the invention, a synthetic cell comprising a compartmentalised gel matrix according to the invention and a synthetic tissue comprising a compartmentalised gel matrix according to the invention.

Abstract: The present invention relates to a series of novel compounds, methods to prevent or treat viral infections in animals by using the novel compounds and to said novel compounds for use as a medicine, more preferably for use as a medicine to treat or prevent viral infections, particularly infections with RNA viruses, more particularly infections with viruses belonging to the family of the Flaviviridae, and yet more particularly infections with the Dengue virus. The present invention furthermore relates to pharmaceutical compositions or combination preparations of the novel compounds, to the compositions or preparations for use as a medicine, more preferably for the prevention or treatment of viral infections. The invention also relates to processes for preparation of the compounds.

Abstract: An intensified continuous process for synthesizing zeolite crystals is described, said process comprising a continuous supply of a continuously prepared gel, said gel then being continuously crystallized, said process comprising at least one application of ultrasound.

Abstract: A method for detecting an analyte in a sample includes the steps of obtaining a nanopore sensor comprising a nanopore and a protein adaptor internalized in the lumen of the nanopore, adding a sample comprising an analyte to the cis side or the trans side of the nanopore, and measuring conductance across the nanopore. A change in conductance after adding the sample indicates the analyte is present in the sample and has bound to the protein adaptor. Nanopore sensors comprise a nanopore and a protein adaptor internalized in the lumen of the nanopore. The protein adaptor is a functional enzyme or ligand-binding protein.

Abstract: A system for generating a mask for object instances in an image is provided. The system includes a first module comprising a trained neural network and configured to input the image to the neural network, wherein the neural network is configured to generate: pixel offset vectors for the pixels of the object instance configured to point towards a unique center of an object instance, the pixel offset vectors thereby forming a cluster with a cluster distribution, and for each object instance an estimate of said cluster distribution defining a margin for determining which pixels belong to the object instance. A method for training a neural network map to be used for generating a mask for object instances in an image is also provided.

Abstract: The present invention relates to a series of novel compounds, methods to prevent or treat viral infections in animals by using the novel compounds and to said novel compounds for use as a medicine, more preferably for use as a medicine to treat or prevent viral infections, particularly infections with RNA viruses, more particularly infections with viruses belonging to the family of the Flaviviridae, and yet more particularly infections with the Dengue virus. The present invention furthermore relates to pharmaceutical compositions or combination preparations of the novel compounds, to the compositions or preparations for use as a medicine, more preferably for the prevention or treatment of viral infections. The invention also relates to processes for preparation of the compounds.

Abstract: A miniaturized, automated method for controlled printing of large arrays of nano- to femtoliter droplets by actively transporting mother droplets over hydrophilic-in-hydrophobic (“HIH”) micropatches. The technology uses single or double-plate devices where mother droplets can be actuated and HIH micropatches on one or both plates of the device where the droplets are printed. Due to the selective wettability of the hydrophilic micropatches in a hydrophobic matrix, large nano- to femtoliter droplet arrays are created when mother droplets are transported over the arrays. The parent droplets are moved by various droplet actuation principles. Also, a method using two plates placed one top another while being separated by a spacer. One plate is dedicated to confirming and guiding parent droplets by using hydrophilic patches in a hydrophobic matrix, while the other plate contains HIH arrays for printing of the droplets.

Abstract: The present invention describes in vitro methods for producing a cellular composition with in vivo bone forming potential.

Abstract: The present invention provides an oral care composition comprising: (a) a dipeptide of the formula Xaa1-Xaa2 or Xaa2-Xaa1; wherein Xaa1 is an amino acid with a polar uncharged side chain; and Xaa2 is selected from an amino acid with a hydrophobic side chain, an amino acid with a polar uncharged side chain, and proline; or (b) a dipeptide of the formula Xaa3-Xaa4 or Xaa4-Xaa3; wherein Xaa3 is an amino acid with a hydrophobic side chain; and Xaa4 is selected from an amino acid with a hydrophobic side chain and an amino acid with a charged side chain.

Abstract: Example embodiments relate to single-photon avalanche diode detector (SPAD) arrays. One embodiment includes a SPAD array that includes a silicon substrate, a plurality of primary electrodes, and a plurality of secondary electrodes. Each of the primary electrodes includes a semiconductor material of a first doping type, extends in the silicon substrate in a first direction, and has a rotationally symmetric cross-section in a first plane perpendicular to the first direction. The plurality of secondary electrodes includes a semiconductor material of a second doping type and extends parallel to the primary electrodes in the silicon substrate. Further, the silicon substrate includes a doped upper field redistribution layer, a doped lower field redistribution layer, and a doped depletion layer arranged between the upper field redistribution layer and the lower field redistribution layer.

Abstract: Described herein are nanopore biosensors based on a modified cytolysin protein. The nanopore biosensors accommodate macromolecules including proteins and nucleic acids, and may additionally comprise ligands with selective binding properties.

Abstract: At least one embodiment relates to a focusing arrangement for focusing particles or cells in a flow. The arrangement includes at least one channel for guiding the flow. The channel includes (i) at least one particle confinement structure having particle flow boundaries and (ii) at least one acoustic confinement structure having acoustic field boundaries adapted for confining acoustic fields. The acoustic field boundaries may be different from the particle flow boundaries, and the at least one acoustic confinement structure may be arranged with regard to the channel to at least partially confine acoustic fields in the channel.

Abstract: This application relates to the field of neurodegenerative diseases, more particularly to the field of Parkinson's disease. In particular, the disclosure describes that inhibitors reducing FAS activity can be used for treatment of Parkinson's disease, in particular, the treatment of patients suffering from Parkinson's disease having loss of function mutations in PINK1 or PARKIN genes.

Abstract: A balloon catheter (100), suitable for delivery of a balloon to the stomach via application by the nose, the balloon catheter comprising a catheter (2) and one or more inflatable balloons (1) fixedly attached to the catheter. The balloons have an outer diameter from 4 to 7 cm, are made of a relatively hard material (e.g. durometer 70 to 100 shore A), and have an effective length of 7 to 18 cm or a total inner volume of 90 to 330 ml, when inflated by 0.2 psi. A system comprising the balloon catheter, and a pressure sensor for measuring a pressure of a fluid inside the balloon, and optionally a fluid pump for inflating and/or deflating the balloon, and a control unit for reading the pressure sensor and optionally for controlling the fluid pump.

Abstract: The application relates to the field of cancer, particularly to the field of solid tumors. It was found that a particular long non-coding RNA (lncRNA), NEAT1, an essential architectural component of nuclear paraspeckles, is required for the survival of cancer, but not that of normal, non-transformed, cells. Inhibition of NEAT1 reduces cell viability of cancer cells and induces apoptosis. These data identify NEAT1 as a novel therapeutic target for treatment of solid tumors.